Venus Remedies Limited Business Intelligence Report
Venus Remedies Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
No quarterly summary available yet.
AI Summary
Venus Remedies Limited (VSR) is a research-oriented pharmaceutical entity specializing in critical care and oncology, notably as a major producer of Meropenem. The secondary analysis of its 10-year journey reveals a business that has emerged from a period of severe financial distress (FY17-FY20) to a state of debt-free stability and renewed growth. While the business possesses substantial intellectual property with 135+ patents and 1,040+ marketing authorizations, its historical inconsistency in profit delivery and high working capital requirements have suppressed long-term value compounding.…
Key Changes in FY2026
The business has undergone a significant transformation from a debt-laden injectable manufacturer to a research-driven, almost debt-free pharmaceutical entity specializing in Antimicrobial Resistance (AMR) drugs. Over the last decade, Venus evolved by focusing on high-value segments like oncology and neurology while building a massive IP portfolio of 135+ patents. The strategic pivot toward export markets and high-margin marketing authorizations (MAs) is evident in the margin expansion from 10% in 2024 to 19% in 2026. This evolution reflects a successful move up the value chain from commodity generics to specialized formulation research. The company's resilience is marked by its ability to maintain its product basket despite severe financial stress during the 2017-2020 period.
Management Commentary
Management has demonstrated resilience and strategic patience during the recovery phase, successfully navigating a debt-trap scenario that would have bankrupted less disciplined firms. Their focus on the 'AMR' (Antimicrobial Resistance) niche and oncology provides a clear thematic direction for the company. Transparency is moderate; while disclosure of marketing authorizations and patent counts is consistent, more clarity is needed on the revenue mix between domestic and international markets. The promoter holding has marginally increased from 37.5% in FY17 to 41.76%, signaling increased management skin in the game. The successful pivot to a debt-free status is a testament to management execution. However, the long period of stagnant sales growth (7% CAGR over 10y) indicates either market…
Financial Highlights
The financial trajectory of Venus Remedies is characterized by a stark 'U-shaped' recovery; revenue remained stagnant between 400Cr and 330Cr during the 2017-2020 period before scaling toward 770Cr in FY26. Operating margins have historically been compressed around 10-11%, but the recent leap to 19% indicates a pivot toward premiumization and cost efficiency. The most notable financial achievement is the elimination of heavy interest costs, which consumed 41Cr in FY15, down to zero in recent years. Net profit has swung from a loss of 31Cr in FY18 to a record 103Cr in FY26. However, return on equity has been historically low, only recently crossing the 15% threshold. Business quality is improving but requires multi-year sustainability to prove the trend is not cyclical.
Major Opportunities
- Successful transition to near debt-free status from high leverage
- Stellar profit growth (174% TTM) indicating business turnaround
- Strong R&D focus with 135+ patents and 1040+ marketing authorizations
Major Risks
- 歷史 recorded a period of 4 consecutive years of net losses (2017-2020)
- Low average Sales growth of ~7% over 5 and 10-year horizons
- High historical dependence on 'Other Income' to drive net profitability in FY21
About Venus Remedies Limited's Annual Report & Financial Performance
The latest Venus Remedies Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Venus Remedies Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Venus Remedies Limited — Frequently Asked Questions
Explore more Venus Remedies Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.